Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palatability and tolerability of Exjade taken with meals, liquids, or crushed in food
2011-004217-17Phase 4
- Sponsor
- Novartis
- Start
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of deferasirox in Transfusional Siderosis, hemochromatosis (HH), beta thalassemia major and 3 more, sponsored by Novartis. Primary endpoint: Palatability of Exjade.
02
Drugs
deferasirox
03
Conditions
Transfusional Siderosishemochromatosis (HH)beta thalassemia majorsickle cell disease (SCD)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2011-004217-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004217-17.